Chelsea Newren, NP
Family · Barrington, ILNPI 1487298121
Payments from drug & device makers
Across 124 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$344
- AbbVie$333
- Amgen$256
- Pfizer$252
- Novo Nordisk$251
- Lilly USA, LLC$247
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,782100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 13 | $344 |
| AbbVie | 16 | $333 |
| Amgen | 9 | $256 |
| Pfizer | 11 | $252 |
| Novo Nordisk | 12 | $251 |
| Lilly USA, LLC | 11 | $247 |
| AstraZeneca | 8 | $245 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $100 |
| Lundbeck LLC | 3 | $82 |
| GSK | 4 | $72 |
| Merck | 3 | $65 |
| Bayer | 3 | $60 |
| Currax Pharmaceuticals LLC | 4 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Novartis | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Johnson & Johnson | 1 | $23 |
| Exact Sciences | 1 | $20 |
| Tris Pharma Inc | 1 | $18 |
| Cranial Technologies, Inc | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $16 |
| VBI Vaccine (delaware) Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,782 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 411 | $155,723 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $40,485 |
| JardianceEmpagliflozin | 73 | $32,937 |
| XareltoRivaroxaban | 73 | $28,201 |
| FarxigaDapagliflozin Propanediol | 83 | $27,999 |
| MounjaroTirzepatide | 16 | $17,836 |
| RybelsusSemaglutide | 11 | $16,223 |
| OzempicSemaglutide | 12 | $13,971 |
| RexultiBrexpiprazole | 15 | $13,920 |
| EntrestoSacubitril/Valsartan | 29 | $11,796 |
| Atorvastatin Calcium | 643 | $6,029 |
| Rosuvastatin Calcium | 390 | $5,169 |
| Quetiapine Fumarate | 335 | $4,946 |
| Levothyroxine Sodium | 484 | $4,660 |
| Pantoprazole Sodium | 390 | $4,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $252 | $155,723411 claims |
| GSKTrelegy Ellipta | $72 | $40,48552 claims |
| Boehringer IngelheimJardiance | $344 | $32,93773 claims |
| Novo NordiskRybelsus, Ozempic | $251 | $30,19323 claims |
| Johnson & JohnsonXarelto | $23 | $28,20173 claims |
| AstraZenecaFarxiga | $245 | $27,99983 claims |
| Lilly USA, LLCMounjaro | $247 | $17,83616 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $49 | $13,92015 claims |
| NovartisEntresto | $49 | $11,79629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.
Other family in Barrington
- Aleksandra BielawiecBarrington$373K
- Ruth CarricoChicago$582K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.